wikidoc - Recent changes [en]

HMG box gene transcriptions

2026-04-30T20:20:15Z

Helper site samplings

← Older revision		Revision as of 20:20, 30 April 2026
Line 317:		Line 317:

	==Helper site samplings==		==Helper site samplings==
			[[HMG box gene transcriptions#Helper site samplings\|Helper site samplings]]

	For the Basic programs testing consensus sequence (C/G)C(C/G)G(C/G) (starting with SuccessablesHelp.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence (C/G)C(C/G)G(C/G) (starting with SuccessablesHelp.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:

Hibatullah Abdul Aleem

2026-04-29T16:04:52Z

Created page with "__NOTOC__ ==Hibatullah Abdul Aleem== '''Hibatullah Abdul Aleem''' Contact: Email: [mailto:dr.hibatullah8@gmail.com] ==Current Position== ==Professional Background== ==Education== M.B.B.S fron Shadan Institute Of Medical Sciences ==Brief Biography=="

New page

__NOTOC__
==Hibatullah Abdul Aleem==
'''Hibatullah Abdul Aleem'''
 Contact: 
Email: [mailto:dr.hibatullah8@gmail.com] 

==Current Position==

==Professional Background==

==Education==
M.B.B.S fron Shadan Institute Of Medical Sciences

==Brief Biography==

Sandbox

2026-04-29T10:11:34Z

Replaced content with "== '''Thoracic Aortic Aneurysm Medical Therapy''' == <references />"

Show changes

Thoracic aortic aneurysm medical therapy

2026-04-29T10:10:34Z

Medical Therapy

Show changes

SANDBOX:HT

2026-04-29T10:02:24Z

Created page with "HEADING"

New page

[[HEADING]]

Template:HT

2026-04-29T09:46:56Z

Created page with "Hibatullah Abdul Aleem, M.B.B.S[mailto:dr.hibatullah8@gmail.com]"

New page

[[User:Hibatullah Abdul Aleem|Hibatullah Abdul Aleem, M.B.B.S]][mailto:dr.hibatullah8@gmail.com]

Hsf1p gene transcriptions

2026-04-29T09:23:42Z

Hsf (Tang) samplings

← Older revision		Revision as of 09:23, 29 April 2026
(12 intermediate revisions by the same user not shown)
Line 63:		Line 63:

	==Hsf (Tang) samplings==		==Hsf (Tang) samplings==
			[[Hsf1p gene transcriptions#Hsf (Tang) samplings\|Hsf (Tang) samplings]]

	Copying 5'-TGAAA-3' in "⌘F" yields twelve between ZSCAN22 and A1BG and 5'-CGAAC-3' one between ZNF497 and A1BG as can be found by the computer programs.		Copying 5'-TGAAA-3' in "⌘F" yields twelve between ZSCAN22 and A1BG and 5'-CGAAC-3' one between ZNF497 and A1BG as can be found by the computer programs.
Line 379:		Line 380:

	==HSE1 (Eastmond) samplings==		==HSE1 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE1 (Eastmond) samplings\|HSE1 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nGAAnnTTCnnGAAn (starting with SuccessablesHSE1.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nGAAnnTTCnnGAAn (starting with SuccessablesHSE1.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 399:		Line 401:

	==HSE2 (Eastmond) samplings==		==HSE2 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE2 (Eastmond) samplings\|HSE2 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nTTCnnGAAnnTTCn (starting with SuccessablesHSE2.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nTTCnnGAAnnTTCn (starting with SuccessablesHSE2.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 404:		Line 407:

	==HSE3 (Eastmond) samplings==		==HSE3 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE3 (Eastmond) samplings\|HSE3 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nGAAn-(5-bp)-nGAAnnTTCn (starting with SuccessablesHSE3.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nGAAn-(5-bp)-nGAAnnTTCn (starting with SuccessablesHSE3.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 506:		Line 510:

	==HSE4 (Eastmond) samplings==		==HSE4 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE4 (Eastmond) samplings\|HSE4 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nGAAn-(5-bp)-nGAAn-(5-bp)-nGAAn (starting with SuccessablesHSE4.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nGAAn-(5-bp)-nGAAn-(5-bp)-nGAAn (starting with SuccessablesHSE4.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 608:		Line 613:

	==HSE5 (Eastmond) samplings==		==HSE5 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE5 (Eastmond) samplings\|HSE5 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nTTCn-(5-bp)-nTTCnnGAAn (starting with SuccessablesHSE5.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nTTCn-(5-bp)-nTTCnnGAAn (starting with SuccessablesHSE5.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 628:		Line 634:

	==HSE6 (Eastmond) samplings==		==HSE6 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE6 (Eastmond) samplings\|HSE6 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nTTCn-nnGAAn-(5-bp)-nGAAn (starting with SuccessablesHSE6.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nTTCn-nnGAAn-(5-bp)-nGAAn (starting with SuccessablesHSE6.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 648:		Line 655:

	==HSE7 PFT1 (Eastmond) samplings==		==HSE7 PFT1 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE7 PFT1 (Eastmond) samplings\|HSE7 PFT1 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nGA(A/G)nnTTCnnGAAn (starting with Successables PFT1.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nGA(A/G)nnTTCnnGAAn (starting with Successables PFT1.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 668:		Line 676:

	==HSE7 PFT2 (Eastmond) samplings==		==HSE7 PFT2 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE7 PFT2 (Eastmond) samplings\|HSE7 PFT2 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nGAAnnTTCnnGARn (starting with SuccessablesHSE1.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nGAAnnTTCnnGARn (starting with SuccessablesHSE1.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 688:		Line 697:

	==HSE8 GAP1 (Eastmond) samplings==		==HSE8 GAP1 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE8 GAP1 (Eastmond) samplings\|HSE8 GAP1 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nGA(A/G)n-(5-bp)-nGAAnnTTCn (starting with SuccessablesGAP1.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nGA(A/G)n-(5-bp)-nGAAnnTTCn (starting with SuccessablesGAP1.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 794:		Line 804:

	==HSE9 GAP2 (Eastmond) samplings==		==HSE9 GAP2 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE9 GAP2 (Eastmond) samplings\|HSE9 GAP2 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nGAAn-(5-bp)-nGARnnTTCn (starting with SuccessablesGAP2.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nGAAn-(5-bp)-nGARnnTTCn (starting with SuccessablesGAP2.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:
Line 896:		Line 907:

	==HSE10 (Eastmond) samplings==		==HSE10 (Eastmond) samplings==
			[[Hsf1p gene transcriptions#HSE10 (Eastmond) samplings\|HSE10 (Eastmond) samplings]]

	For the Basic programs testing consensus sequence nTTCn-(11-bp)-nGAAn-(5 bp)-nGAAn (starting with SuccessablesHSE3.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence nTTCn-(11-bp)-nGAAn-(5 bp)-nGAAn (starting with SuccessablesHSE3.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:

Heat-responsive element gene transcriptions

2026-04-28T22:40:59Z

HRE samplings

← Older revision		Revision as of 22:40, 28 April 2026
Line 39:		Line 39:
	==HRE samplings==		==HRE samplings==
	{{main\|Model samplings}}		{{main\|Model samplings}}
			[[Heat-responsive element gene transcriptions#HRE samplings\|HRE samplings]]

	Copying an apparent consensus sequence of the HRE AAAAAATTTC and putting it in "⌘F" finds none located between ZSCAN22 and A1BG and none between ZNF497 and A1BG as can be found by the computer programs.		Copying an apparent consensus sequence of the HRE AAAAAATTTC and putting it in "⌘F" finds none located between ZSCAN22 and A1BG and none between ZNF497 and A1BG as can be found by the computer programs.

H box gene transcriptions

2026-04-28T20:29:14Z

H boxes (Rozhdestvensky) in promoters of A1BG

← Older revision		Revision as of 20:29, 28 April 2026
(One intermediate revision by the same user not shown)
Line 403:		Line 403:
	\|accessdate=2014-06-08 }}</ref>		\|accessdate=2014-06-08 }}</ref>

	==H boxes (Rozhdestvensky) ~~in promoters of A1BG~~==		==H boxes (Rozhdestvensky) samplings==
			[[H box gene transcriptions#H boxes (Rozhdestvensky) samplings\|H boxes (Rozhdestvensky) samplings]]

	For the Basic programs (starting with SuccessablesHACA.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs (starting with SuccessablesHACA.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:

Datopotamab deruxtecan-dlnk

2026-04-28T18:44:41Z

← Older revision		Revision as of 18:44, 28 April 2026
Line 292:		Line 292:

	* Store vials in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light until time of reconstitution. Do not freeze. Do not shake the reconstituted or diluted solution.		* Store vials in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light until time of reconstitution. Do not freeze. Do not shake the reconstituted or diluted solution.
			[[File:Datopotamab display panel.jpeg\|400px\|thumb\|right\|Principle Display Panel]]

	* DATROWAY (datopotamab deruxtecan-dlnk) is a hazardous drug. Follow applicable special handling and disposal procedures.		* DATROWAY (datopotamab deruxtecan-dlnk) is a hazardous drug. Follow applicable special handling and disposal procedures.

File:Datopotamab display panel.jpeg

2026-04-28T14:09:42Z

Anum Ijaz uploaded File:Datopotamab display panel.jpeg

New page

H box gene transcriptions

2026-04-28T08:43:16Z

H boxes (Mitchell) samplings

← Older revision		Revision as of 08:43, 28 April 2026
Line 64:		Line 64:

	==H boxes (Mitchell) samplings==		==H boxes (Mitchell) samplings==
			[[H box gene transcriptions#H boxes (Mitchell) samplings\|H boxes (Mitchell) samplings]]

	For the Basic programs testing consensus sequence 3'-ANANNA-5' (starting with SuccessablesHbox3.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs testing consensus sequence 3'-ANANNA-5' (starting with SuccessablesHbox3.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:

Gcr1p gene transcriptions

2026-04-28T05:35:47Z

GCR1 samplings

← Older revision		Revision as of 05:35, 28 April 2026
Line 37:		Line 37:

	==GCR1 samplings==		==GCR1 samplings==
			[[Gcr1p gene transcriptions#GCR1 samplings\|GCR1 samplings]]

	Copying the apparent consensus sequence for Gcr1p CTTCC and putting it in "⌘F" finds four located between ZSCAN22 and six between ZNF497 and A1BG as can be found by the computer programs.		Copying the apparent consensus sequence for Gcr1p CTTCC and putting it in "⌘F" finds four located between ZSCAN22 and six between ZNF497 and A1BG as can be found by the computer programs.

Gibberellin responsive element gene transcriptions

2026-04-28T05:29:57Z

GRE samplings

← Older revision		Revision as of 05:29, 28 April 2026
Line 31:		Line 31:

	==GRE samplings==		==GRE samplings==
			[[Gibberellin responsive element gene transcriptions#GRE samplings\|GRE samplings]]

	Copying an apparent consensus sequence of CCTTTTG, AAACAGA and putting it in "⌘F" finds one located between ZSCAN22 and A1BG and two between ZNF497 and A1BG as can be found by the computer programs.		Copying an apparent consensus sequence of CCTTTTG, AAACAGA and putting it in "⌘F" finds one located between ZSCAN22 and A1BG and two between ZNF497 and A1BG as can be found by the computer programs.

Glucocorticoid response element gene transcriptions

2026-04-28T05:26:41Z

Glu samplings

← Older revision		Revision as of 05:26, 28 April 2026
Line 32:		Line 32:

	==Glu samplings==		==Glu samplings==
			[[Glucocorticoid response element gene transcriptions#Glu samplings\|Glu samplings]]

	Copying an apparent consensus sequence of AGAACA and putting it in "⌘F" finds one located between ZSCAN22 and A1BG and two between ZNF497 and A1BG as can be found by the computer programs.		Copying an apparent consensus sequence of AGAACA and putting it in "⌘F" finds one located between ZSCAN22 and A1BG and two between ZNF497 and A1BG as can be found by the computer programs.

Grainy head transcription factor gene transcriptions

2026-04-28T05:24:41Z

Mouse grainy head samplings

← Older revision		Revision as of 05:24, 28 April 2026
(One intermediate revision by the same user not shown)
Line 40:		Line 40:

	==Mouse grainy head samplings==		==Mouse grainy head samplings==
			[[Grainy head transcription factor gene transcriptions#Mouse grainy head samplings\|Mouse grainy head samplings]]

	Copying the GRHL1 DNA‐binding consensus sequence AACCGGTT and putting it in "⌘F" finds none located between ZSCAN22 and A1BG and none between ZNF497 and A1BG as can be found by the computer programs.		Copying the GRHL1 DNA‐binding consensus sequence AACCGGTT and putting it in "⌘F" finds none located between ZSCAN22 and A1BG and none between ZNF497 and A1BG as can be found by the computer programs.
Line 62:		Line 63:

	==Human grainy head transcription factor samplings==		==Human grainy head transcription factor samplings==
			[[Grainy head transcription factor gene transcriptions#Human grainy head transcription factor samplings\|Human grainy head transcription factor samplings]]

	Copying a responsive elements consensus sequence GACTGGTT and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence GACTGGTT and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.

Hac1p gene transcriptions

2026-04-28T05:21:37Z

KAR2 samplings

← Older revision		Revision as of 05:21, 28 April 2026
Line 39:		Line 39:
	==''KAR2'' samplings==		==''KAR2'' samplings==
	{{main\|Model samplings}}		{{main\|Model samplings}}
			[[Hac1p gene transcriptions#''KAR2'' samplings\|''KAR2'' samplings]]

	Copying 5'-CAGCGTG-3' in "⌘F" yields none between ZSCAN22 and A1BG and none between ZNF497 and A1BG as can be found by the computer programs.		Copying 5'-CAGCGTG-3' in "⌘F" yields none between ZSCAN22 and A1BG and none between ZNF497 and A1BG as can be found by the computer programs.

H and ACA box gene transcriptions

2026-04-28T05:19:34Z

H and ACA boxes in promoters of A1BG

← Older revision		Revision as of 05:19, 28 April 2026
Line 41:		Line 41:

	==H and ACA boxes in promoters of A1BG==		==H and ACA boxes in promoters of A1BG==
			[[H and ACA box gene transcriptions#H and ACA boxes in promoters of A1BG\|H and ACA boxes in promoters of A1BG]]

	For the Basic programs (starting with SuccessablesHACA.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:		For the Basic programs (starting with SuccessablesHACA.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), the programs are, are looking for, and found:

Middle sporulation element gene transcriptions

2026-04-28T05:15:09Z

HAP2 samplings

← Older revision		Revision as of 05:15, 28 April 2026
Line 408:		Line 408:
	==HAP2 samplings==		==HAP2 samplings==
	{{main\|Model samplings}}		{{main\|Model samplings}}
			[[Middle sporulation element gene transcriptions#HAP2 samplings\|HAP2 samplings]]

	Copying a responsive elements consensus sequence CCAATCA and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence CCAATCA and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.

Endoplasmic reticulum stress response element gene transcriptions

2026-04-28T05:09:36Z

CCAAT samplings

← Older revision		Revision as of 05:09, 28 April 2026
Line 21:		Line 21:

	==CCAAT samplings==		==CCAAT samplings==
			[[Endoplasmic reticulum stress response element gene transcriptions#CCAAT samplings\|CCAAT samplings]]

	Copying an apparent consensus sequence of CCAAT and putting it in "⌘F" finds none located between ZSCAN22 and A1BG on the negative strand and finds one on the positive strand but CCAAT-1A-2T-3T-4T5T-6A-7A-8A-9GT finds none and CCAAT occurs once between ZNF497 and A1BG but CCAAT-1G-2G-3G-4C-5T-6G-7A-8A-9AC finds none between ZNF497 and A1BG on the negative strand and CCAAT occurs once between ZNF497 and A1BG but CCAAT-1A-2C-3T-4G-5A-6A-7G-8T-9CCG finds none on the positive strand as can be found by the computer programs.		Copying an apparent consensus sequence of CCAAT and putting it in "⌘F" finds none located between ZSCAN22 and A1BG on the negative strand and finds one on the positive strand but CCAAT-1A-2T-3T-4T5T-6A-7A-8A-9GT finds none and CCAAT occurs once between ZNF497 and A1BG but CCAAT-1G-2G-3G-4C-5T-6G-7A-8A-9AC finds none between ZNF497 and A1BG on the negative strand and CCAAT occurs once between ZNF497 and A1BG but CCAAT-1A-2C-3T-4G-5A-6A-7G-8T-9CCG finds none on the positive strand as can be found by the computer programs.

CAAT box gene transcriptions

2026-04-28T05:08:04Z

Heme-activated protein (Hap) samplings

← Older revision		Revision as of 05:08, 28 April 2026
(One intermediate revision by the same user not shown)
Line 211:		Line 211:

	==Heme-activated protein (Hap) samplings==		==Heme-activated protein (Hap) samplings==
			[[CAAT box gene transcriptions#Heme-activated protein (Hap) samplings\|Heme-activated protein (Hap) samplings]]

	Copying the consensus sequence for the Hap4p CCAAT and putting the sequence in "⌘F" finds one location between ZNF497 and A1BG or no locations between ZSCAN22 and A1BG as can be found by the computer programs.		Copying the consensus sequence for the Hap4p CCAAT and putting the sequence in "⌘F" finds one location between ZNF497 and A1BG or no locations between ZSCAN22 and A1BG as can be found by the computer programs.

H box gene transcriptions

2026-04-28T05:00:13Z

H-box (Lindsay) samplings

← Older revision		Revision as of 05:00, 28 April 2026
(One intermediate revision by the same user not shown)
Line 583:		Line 583:
	==H-box (Grandbastien) samplings==		==H-box (Grandbastien) samplings==
	{{main\|Model samplings}}		{{main\|Model samplings}}
			[[H box gene transcriptions#H-box (Grandbastien) samplings\|H-box (Grandbastien) samplings]]

	Copying a responsive elements consensus sequence CCTACCTGGCGGAT and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or CCTACC finds none between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence CCTACCTGGCGGAT and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or CCTACC finds none between ZSCAN22 and A1BG as can be found by the computer programs.

Line 698:		Line 700:
	==H-box (Lindsay) samplings==		==H-box (Lindsay) samplings==
	{{main\|Model samplings}}		{{main\|Model samplings}}
			[[H box gene transcriptions#H-box (Lindsay) samplings\|H-box (Lindsay) samplings]]

	Copying a responsive element consensus sequence CCTACC and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or one between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive element consensus sequence CCTACC and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or one between ZSCAN22 and A1BG as can be found by the computer programs.

Sandbox

2026-04-28T01:40:03Z

← Older revision		Revision as of 01:40, 28 April 2026
Line 30:		Line 30:
	* [[Statin\|Statins]]: high-intensity statin therapy for atherosclerotic TAA		* [[Statin\|Statins]]: high-intensity statin therapy for atherosclerotic TAA

	== 2022 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease <ref name="pmid36334952">{{cite journal \|vauthors=Isselbacher EM, Preventza O, Hamilton Black Iii J, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A, Fanola CL, Girardi LN, Hicks CW, Hui DS, Jones WS, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Ross EG, Schermerhorn ML, Times SS, Tseng EE, Wang GJ, Woo YJ \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=J Am Coll Cardiol \|volume=80 \|issue=24 \|pages=e223–e393 \|date=December 2022 \|pmid=36334952 \|pmc=9860464 \|doi=10.1016/j.jacc.2022.08.004 \|url=}}</ref> <ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC">{{cite web \|url=https://www.jacc.org/doi/10.1016/j.jacc.2022.08.004 \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC \|format= \|work= \|accessdate=}}</ref> ==		==2022 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease <ref name="pmid36334952">{{cite journal \|vauthors=Isselbacher EM, Preventza O, Hamilton Black Iii J, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A, Fanola CL, Girardi LN, Hicks CW, Hui DS, Jones WS, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Ross EG, Schermerhorn ML, Times SS, Tseng EE, Wang GJ, Woo YJ \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=J Am Coll Cardiol \|volume=80 \|issue=24 \|pages=e223–e393 \|date=December 2022 \|pmid=36334952 \|pmc=9860464 \|doi=10.1016/j.jacc.2022.08.004 \|url=}}</ref> <ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC">{{cite web \|url=https://www.jacc.org/doi/10.1016/j.jacc.2022.08.004 \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC \|format= \|work= \|accessdate=}}</ref>==

	=== Multidisciplinary Aortic Team and Shared Decision-Making<ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC" /> ===		=== Multidisciplinary Aortic Team and Shared Decision-Making<ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC" /> ===
Line 185:		Line 185:

	== '''References''' ==		== '''References''' ==
			<references />

Datopotamab deruxtecan-dlnk

2026-04-28T00:58:04Z

Show changes

Sandbox

2026-04-28T00:07:58Z

Multidisciplinary Aortic Team and Shared Decision-Making[2]

Show changes

Datopotamab deruxtecan-dlnk

2026-04-27T23:52:27Z

Sandbox

2026-04-27T23:15:44Z

Show changes

Atrial fibrillation

2026-04-27T21:51:47Z

Rhythm Control

Show changes

User:Hasnain Ali

2026-04-27T20:24:40Z

← Older revision		Revision as of 20:24, 27 April 2026
Line 10:		Line 10:
	I create original content on my areas of interest and refresh older chapters to keep the medical information current.		I create original content on my areas of interest and refresh older chapters to keep the medical information current.

	* Resident ~~Medical Officer with Dept. of Neurology~~, Liaquat University hospital Hyderabad/Jamshoro, Pakistan.		* Resident, Liaquat University hospital Hyderabad/Jamshoro, Pakistan.

	I provide inpatient and outpatient neurological care, managing up to 5 inpatients daily and around 30 clinic and emergency patients per week. Alongside clinical duties, I participated in multidisciplinary academic activities and contributed to research through systematic data collection and documentation.		I provide inpatient and outpatient neurological care, managing up to 5 inpatients daily and around 30 clinic and emergency patients per week. Alongside clinical duties, I participated in multidisciplinary academic activities and contributed to research through systematic data collection and documentation.

Industrial and organizational psychology

2026-04-27T20:07:19Z

Career calling

← Older revision		Revision as of 20:07, 27 April 2026
Line 185:		Line 185:

	Career calling can be promoted by a career calling climate at work<ref name="Chen 2025">{{cite journal \| last1=Chen \| first1=Jiatian \| last2=May \| first2=Douglas R. \| last3=Schwoerer \| first3=Catherine E. \| title=Career calling climate: The development and validation of a scale for a new construct \| journal=Journal of Management & Organization \| volume=31 \| issue=4 \| date=2025 \| issn=1833-3672 \| doi=10.1017/jmo.2023.16 \| pages=1688–1707 \| url=https://www.cambridge.org/core/product/identifier/S1833367223000160/type/journal_article \| access-date=2026-04-27}}</ref>.		Career calling can be promoted by a career calling climate at work<ref name="Chen 2025">{{cite journal \| last1=Chen \| first1=Jiatian \| last2=May \| first2=Douglas R. \| last3=Schwoerer \| first3=Catherine E. \| title=Career calling climate: The development and validation of a scale for a new construct \| journal=Journal of Management & Organization \| volume=31 \| issue=4 \| date=2025 \| issn=1833-3672 \| doi=10.1017/jmo.2023.16 \| pages=1688–1707 \| url=https://www.cambridge.org/core/product/identifier/S1833367223000160/type/journal_article \| access-date=2026-04-27}}</ref>.

			Calling may increase engagement at work, especially is organizational commitment is present<ref name="Cao2019">{{cite journal \| last1=Cao \| first1=Yudi \| last2=Liu \| first2=Jingying \| last3=Liu \| first3=Kejia \| last4=Yang \| first4=Mengyu \| last5=Liu \| first5=Yanhui \| title=The mediating role of organizational commitment between calling and work engagement of nurses: A cross-sectional study \| journal=International Journal of Nursing Sciences \| volume=6 \| issue=3 \| date=2019-07-10 \| issn=2352-0132 \| pmid=31508452 \| pmc=6722477 \| doi=10.1016/j.ijnss.2019.05.004 \| pages=309–314 \| url=https://pubmed.ncbi.nlm.nih.gov/31508452 \| access-date=2026-04-27}}</ref> as measured by the organizational commitment scale (OCS)<ref name="Allen2011">{{cite journal \| last1=Allen \| first1=Natalie J. \| last2=Meyer \| first2=John P. \| title=The measurement and antecedents of affective, continuance and normative commitment to the organization \| journal=Journal of Occupational Psychology \| volume=63 \| issue=1 \| date=1990 \| issn=0305-8107 \| doi=10.1111/j.2044-8325.1990.tb00506.x \| pages=1–18 \| url=https://bpspsychub.onlinelibrary.wiley.com/doi/10.1111/j.2044-8325.1990.tb00506.x \| access-date=2026-04-27}}</ref>.

	===Satisfaction===		===Satisfaction===

← Older revision		Revision as of 23:52, 27 April 2026
Line 45:		Line 45:
	DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.		DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.

	Locally Advanced or Metastatic NSCLC		'''Locally Advanced or Metastatic NSCLC''

	In the pooled safety population of 484 patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01 ~~[see Adverse Reactions (6.1)]~~, ILD/pneumonitis occurred in 7% of patients treated with DATROWAY, including 0.6% of patients with Grade 3 and 0.4% with Grade 4. There were 8 (1.7%) fatal cases. The median time to onset for ILD was 1.4 months (range: 0.2 months to 9 months). Eleven patients (2.3%) had DATROWAY withheld and 20 patients (4.1%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 79% (26/33) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 45% of patients.		In the pooled safety population of 484 patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01, ILD/pneumonitis occurred in 7% of patients treated with DATROWAY, including 0.6% of patients with Grade 3 and 0.4% with Grade 4. There were 8 (1.7%) fatal cases. The median time to onset for ILD was 1.4 months (range: 0.2 months to 9 months). Eleven patients (2.3%) had DATROWAY withheld and 20 patients (4.1%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 79% (26/33) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 45% of patients.

	Unresectable or Metastatic Breast Cancer		Unresectable or Metastatic Breast Cancer
Line 86:		Line 86:


	The safety of DATROWAY was evaluated in 125 patients with EGFR-mutated NSCLC who received DATROWAY 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity in TROPION-Lung05 and TROPION-Lung01 ~~[see Clinical Studies (14.1)]~~ as well as TROPION-PanTumor01 (NCT03401385). Among these patients, the median duration of treatment was 6.1 months (range 0.7 months to 41.7 months).		The safety of DATROWAY was evaluated in 125 patients with EGFR-mutated NSCLC who received DATROWAY 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity in TROPION-Lung05 and TROPION-Lung01 as well as TROPION-PanTumor01 (NCT03401385). Among these patients, the median duration of treatment was 6.1 months (range 0.7 months to 41.7 months).

	The median age was 63 years (range: 36 to 81), 56% of patients were <65 years, 62% of patients were female; 66% were Asian, 26% were White, 0.8% were Black, 6% were other races; and 2.4% were of Hispanic ethnicity.		The median age was 63 years (range: 36 to 81), 56% of patients were <65 years, 62% of patients were female; 66% were Asian, 26% were White, 0.8% were Black, 6% were other races; and 2.4% were of Hispanic ethnicity.
Line 161:		Line 161:

	Reconstitute immediately before dilution.		Reconstitute immediately before dilution.
	More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted DATROWAY solution required, and the number of vial(s) of DATROWAY needed ~~[see Dosage and Administration (2.2)]~~.		More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted DATROWAY solution required, and the number of vial(s) of DATROWAY needed.
	Reconstitute each 100 mg vial using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection into each vial to obtain a final concentration of 20 mg/mL.		Reconstitute each 100 mg vial using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection into each vial to obtain a final concentration of 20 mg/mL.
	Swirl the vial gently until completely dissolved. Do not shake.		Swirl the vial gently until completely dissolved. Do not shake.
Line 286:		Line 286:
	Interstitial Lung Disease/Pneumonitis		Interstitial Lung Disease/Pneumonitis

	Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms ~~[see Warnings and Precautions (5.1)]~~.		Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms.
	Ocular Adverse Reactions		Ocular Adverse Reactions

	Inform patients about the need for eye exams at initiation and during treatment with DATROWAY ~~[see Dosage and Administration (2.3)]~~.		Inform patients about the need for eye exams at initiation and during treatment with DATROWAY .
	Advise patients to contact their healthcare provider if they experience any eye symptoms.		Advise patients to contact their healthcare provider if they experience any eye symptoms.
	Advise patients to use preservative-free lubricating eye drops several times daily and to avoid use of contact lenses during treatment with DATROWAY.		Advise patients to use preservative-free lubricating eye drops several times daily and to avoid use of contact lenses during treatment with DATROWAY.